Skip to main content

AXSM

Stock
Health Care
Biotechnology

Performance overview

AXSM Price
Price Chart

Forward-looking statistics

Beta
0.84
Risk
53.48%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

axsome therapeutics is a biopharmaceutical company developing novel therapies for the treatment of cns disorders. axsome has a balanced portfolio of clinical development stage as well as research stage product candidates. the company is based in new york city.

Company info

SectorHealth Care
IndustryBiotechnology
Employees461
Market cap$3.5B

Fundamentals

Enterprise value$5.1B
Revenue$432.2M
Revenue per employee—
Profit margin-64.39%
Debt to equity397.01

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$5.77
Dividend per share—
Revenue per share$8.95
Avg trading volume (30 day)$69M
Avg trading volume (10 day)$69M
Put-call ratio—

Macro factor sensitivity

Growth-0.5
Credit+7.0
Liquidity+2.2
Inflation-3.2
Commodities+0.8
Interest Rates-2.5

Valuation

Dividend yield0.00%
PEG Ratio-48.81
Price to sales12.01
P/E Ratio-48.81
Enterprise Value to Revenue11.69
Price to book97.54

Upcoming events

Next earnings dayMay 5, 2025
Next dividend day—
Ex. dividend day—

News

Why Is Axsome (AXSM) Down 1.8% Since Last Earnings Report?

Axsome (AXSM) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research (June 4, 2025)
Axsome Therapeutics Clocks Around 60% Topline Growth In Q1

Axsome Therapeutics IncĀ  AXSM on Monday reported first-quarter 2025 revenues of $121.5 million, up from $75 million a year ago, beating theĀ consensus of $119.87 million.

Benzinga (May 5, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free